Japan
Oncolys BioPharma Inc. is a Tokyo-based bioventure established in Japan in March 2004. The company's mission is to contribute to the advancement of medical science through innovation in cancer and infectious disease treatments, utilizing virology-based new drug discovery technologies.
The company operates in two business segments. The Pharmaceutical Business segment focuses on research, development, manufacturing, and marketing of novel drugs. Its major pipeline includes Telomelysin (OBP-301), an oncolytic adenovirus immunotherapy in clinical development targeting various solid tumors like melanoma, HCC, and esophageal cancer. Besides, the company is also developing an anti-HIV drug OBP-601 (Censavudine) and a novel HDAC inhibitor OBP-801 in the United States. The Diagnostics Business segment is involved in the research, development, manufacture, and marketing of CTC (Circulating Tumor Cell) detection adenovirus TelomeScan, in addition to providing inspection services.
Oncolys was listed on the Tokyo Stock Exchange Mothers Market in December 2014 and has a clinical laboratory center in Kobe, Japan and a subsidiary in New Jersey, USA. The company's focus on leveraging virology-based technologies places it at the forefront of innovation in cancer and infectious disease treatments, making it an intriguing prospect for potential venture capital investment.
